Article

CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias

2025-10-21

Abstract excerpt

<title>Abstract</title> <p>CD19-directed chimeric antigen receptor T-cell therapy (CAR19) improves survival in patients with relapsed/refractory large B-cell lymphoma (rrLBCL) compared to immunochemotherapy with intent for autologous hematopoietic cell transplantation (HCT). However, major toxicities of CAR19 therapy include prolonged cytopenias, infection, and secondary hematologic malignancies. To investigate t...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f6aab897-8f41-55c5-8d1e-1aed1c3d89e0
DOI: 10.21203/rs.3.rs-7746241/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopeniasDOI 10.21203/rs.3.rs-7746241/v1Read

Clonal hematopoiesis is associated with increased toxicity in large B-cell lymphoma patients treated with chimeric antigen receptor T cell therapySemantic proximity Read

Genomic drivers of large B-cell lymphoma resistance to CD19 CAR-T therapySemantic proximity Read

CD22-CAR T cell multiomic features linked to patient outcomes in CD19-CAR resistant large B cell lymphomaSemantic proximity Read

Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated PatientsSemantic proximity Read

Distinct cellular dynamics associated with response to CAR-T therapy for refractory B-cell lymphomaSemantic proximity Read

Hematopoiesis and immune reconstitution after CD19 directed chimeric antigen receptor T‐cells (CAR‐T): A comprehensive review on incidence, risk factors and current managementSemantic proximity Read

CAR+ and CAR− T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignanciesSemantic proximity Read

Patterns of leukocyte recovery predict infectious complications after CD19 CAR-T cell therapy in a real-world settingSemantic proximity Read

Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment.Semantic proximity Read

Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to managementSemantic proximity Read

Anti-CD7 allogeneic WU-CART-007 in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma: a phase 1/2 trialSemantic proximity Read

Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignanciesSemantic proximity Read